Jason Rhodes

Director

Jason Rhodes is a Partner at Atlas Venture and focuses on the creation, development and business strategy of novel therapeutics companies. He is a founder and the chairman and acting CEO of Disarm Therapeutics and Torus Therapeutics and is a member of the board of directors of Replimune, Gemini Therapeutics, Accent Therapeutics, and Bicycle Therapeutics. Prior to joining Atlas in 2014, Jason was President and Chief Financial Officer of Epizyme, Inc. (NASDAQ: EPZM), a public biopharmaceutical company. Prior to Epizyme, Jason led business development at Alnylam (NASDAQ: ALNY). Prior to Alnylam, Jason was a founder and partner with Fidelity Biosciences (now F-Prime Capital Partners), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including Ironwood Pharmaceuticals (NASDAQ: IRWD), FoldRx (purchased by Pfizer), Tetraphase (NASDAQ: TTPH) and Mersana (NASDAQ: MRSN). He holds a BA from Yale University and an MBA from the Wharton School of the University of Pennsylvania.